NDA 021073 · Takeda Pharms USA
Actos
Pioglitazone Hydrochloride · Oral
NovelPriority reviewLast checked: Nov 19, 2026Latest source record: Dec 21, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1999
Jul 15, 1999
Approved uses
6
Original approval plus efficacy supplements
Registered trials
524
126 Phase 3, 31 recruiting
FAERS reports
43,198
30,844 serious, 4,332 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: CONGESTIVE HEART FAILURE • Thiazolidinediones, including ACTOS ® , cause or exacerbate congestive heart failure in some patients [see Warnings and Precautions (5.1) ] . • After initiation of ACTOS, and after dose increases, monitor patients carefully for signs and symptoms of heart failure (e.g., excessive, rapid weight gain, dyspnea, and/or edema). If heart failure develops, it should be managed according to current standards of care and discontinuation or dose reduction of ACTOS must be considered. • ACTOS is not recommended in patients with symptomatic heart failure. • Initiation of ACTOS in patients with established New York Heart Association (NYHA) Class III or IV heart failure is contraindicated [see Contraindications (4) and Warnings and Precautions (5.1) ] . WARNING: CONGESTIVE HEART FAILURE See full prescribing information for complete boxed warning. •...
What it is approved for
From the label in effect Mar 28, 2025.
Monotherapy and Combination Therapy ACTOS is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings [see Clinical Studies (14) ] . Important Limitations of Use ACTOS exerts its antihyperglycemic effect only in the presence of endogenous insulin. ACTOS should not be used to treat type 1 diabetes or diabetic ketoacidosis, as it would not be effective in these settings. Use caution in patients with liver disease [see Warnings and Precautions (5.3) ] . ACTOS is a thiazolidinedione and an agonist for peroxisome proliferator-activated receptor (PPAR) gamma indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings. ( 1 , 14 ) Important Limitations of Use: • Not for treatment of type 1 diabetes or diabetic ketoacidosis. ( 1)
Mechanism: ACTOS is a thiazolidinedione that depends on the presence of insulin for its mechanism of action. ACTOS decreases insulin resistance in the periphery and in the liver resulting in increased insulin-dependent glucose disposal and decreased hepatic glucose output. Pioglitazone is not an insulin secretagogue. Pioglitazone is an agonist for peroxisome proliferator-activated receptor-gamma (PPARγ). PPAR receptors are found in tissues important for insulin action such as adipose tissue, skeletal muscle, and liver. Activation of PPARγ nuclear receptors modulates the transcription of a number of...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 12, 2016 Supplement 48 · Efficacy LetterLabel
- Feb 25, 2007 Supplement 26 · Efficacy LetterLabel
- Nov 26, 2003 Supplement 20 · Efficacy ReviewLetterLabel
- Jan 17, 2003 Supplement 17 · Efficacy Letter
- Jul 12, 2002 Supplement 10 · Efficacy LetterReviewLabel
- Jul 15, 1999 Original approval · Type 1 - New Molecular Entity · priority review ReviewLabelLetter
3 products under this application
- ACTOS · PIOGLITAZONE HYDROCHLORIDE EQ 45MG BASE · TABLET, ORAL · Prescription · TE AB
- ACTOS · PIOGLITAZONE HYDROCHLORIDE EQ 15MG BASE · TABLET, ORAL · Prescription · TE AB
- ACTOS · PIOGLITAZONE HYDROCHLORIDE EQ 30MG BASE · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Pioglitazone" as an intervention, any sponsor and status, largest first.
- Action to Control Cardiovascular Risk in Diabetes (ACCORD)Pivotal-lookingCompleted
National Heart, Lung, and Blood Institute (NHLBI)NIH
NCT00000620 · 10,251 participants · Start Sep 1999 · Primary completion Jun 2009
Drug: Anti-hyperglycemic Agents; Anti-hypertensive Agents and 1 more · For: Atherosclerosis; Cardiovascular Diseases; Hypercholesterolemia and 4 more
Sites: Minneapolis, Minnesota; New York, New York; Winston-Salem, North Carolina · 7 sites in all
- Efficacy of Pioglitazone on Macrovascular Outcome in Patients With Type 2 DiabetesPivotal-lookingCompleted
TakedaTakeda (TAK)
NCT00174993 · 4,373 participants · Start May 2001 · Primary completion Jan 2005
Drug: Pioglitazone; Placebo · For: Diabetes Mellitus
Sites: Multiple Cities, Austria; Multiple Cities, Belgium; Multiple Cities, Czechia · 19 sites in all
- Insulin Resistance Intervention After Stroke TrialPivotal-lookingCompleted
Yale UniversityAcademic, hospital or other
NCT00091949 · 3,876 participants · Start Feb 2005 · Primary completion Nov 2015
Drug: pioglitazone; placebo · For: Stroke; Myocardial Infarction; Diabetes
Sites: Birmingham, Alabama; Mobile, Alabama; Tucson, Arizona · 183 sites in all
- Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its OnsetPivotal-lookingTerminated
TakedaTakeda (TAK)
NCT01931566 · 3,494 participants · Start Aug 1, 2013 · Primary completion Jul 24, 2018
Drug: Pioglitazone; Pioglitazone placebo · For: Mild Cognitive Impairment Due to Alzheimer's Disease
Sites: Phoenix, Arizona; Sun City, Arizona; Long Beach, California · 55 sites in all
- Thiazolidinediones Or Sulphonylureas and Cardiovascular Accidents.Intervention TrialPivotal-lookingStatus unknown
Italian Society of DiabetologyAcademic, hospital or other
NCT00700856 · 3,371 participants (planned) · Start Sep 2008 · Primary completion Dec 2018
Drug: add-on pioglitazone; add-on sulphonylurea · For: Type 2 Diabetes Mellitus; Cardiovascular Disease
Sites: Seriate, Italy; Treviglio, Italy; Lanciano, Italy · 61 sites in all
- Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 DiabetesPivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT01289990 · 2,705 participants · Start Feb 2011 · Primary completion May 2013
Drug: BI 10773; Placebo and 28 more · For: Diabetes Mellitus, Type 2
Sites: Birmingham, Alabama; Glendale, Arizona; Mesa, Arizona · 243 sites in all
- Safety and Efficacy of Vildagliptin vs. Thiazolidinedione as add-on Therapy to Metformin in Patients With Type 2 Diabetes Not Controlled With Metformin AlonePivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00396227 · 2,665 participants · Start Oct 2006 · Primary completion Oct 2007
Drug: vildagliptin; thiazolidinedione (TZD) · For: Diabetes Mellitus, Type 2
Sites: East Hanover, New Jersey
- Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DMPivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT00736099 · 2,122 participants · Start Aug 2008 · Primary completion Dec 2010
Drug: linagliptine 5 mg; linagliptine 5 mg and pioglitazone 30 mg · For: Diabetes Mellitus, Type 2
Sites: Chula Vista, California; Spring Valley, California; Walnut Creek, California · 232 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- bladder cancer8,740
- blood glucose increased3,398
- nausea3,007
- weight decreased2,092
- diarrhoea1,757
- death1,553
- fatigue1,532
- drug ineffective1,513
- vomiting1,495
- dyspnoea1,426
- dizziness1,422
- decreased appetite1,420
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 870 |
| 2005 | 1,323 |
| 2006 | 2,362 |
| 2007 | 2,679 |
| 2008 | 1,644 |
| 2009 | 1,880 |
| 2010 | 2,186 |
| 2011 | 3,106 |
| 2012 | 2,039 |
| 2013 | 1,282 |
| 2014 | 1,127 |
| 2015 | 6,601 |
| 2016 | 3,836 |
| 2017 | 1,859 |
| 2018 | 1,860 |
| 2019 | 1,684 |
| 2020 | 1,378 |
| 2021 | 1,090 |
| 2022 | 984 |
| 2023 | 906 |
| 2024 | 952 |
| 2025 | 913 |
| 2026 | 637 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Actos (Pioglitazone HCl)
2024 spending
$650K
Beneficiaries
168
625 claims
Per beneficiary
$3,872
$16.54 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $2,092,476 |
| 2021 | $1,749,928 |
| 2022 | $1,353,112 |
| 2023 | $947,844 |
| 2024 | $650,459 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Sanyal AJ, Chalasani N, Kowdley KV, et al. · N Engl J Med 2010 · Clinical Trial, Phase III, Comparative Study
- Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.
Cusi K, Orsak B, Bril F, et al. · Ann Intern Med 2016 · Randomized Controlled Trial
- Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.
Dormandy JA, Charbonnel B, Eckland DJ, et al. · Lancet 2005 · Clinical Trial, Multicenter Study
- Pioglitazone Therapy and Fractures: Systematic Review and Meta- Analysis.
Pavlova V, Filipova E, Uzunova K, et al. · Endocr Metab Immune Disord Drug Targets 2018 · Meta-Analysis, Systematic Review
- Efficacy and Safety of High-Dose Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial.
Hong JH, Han KA, Hwang YC, et al. · Diabetes Metab J 2026 · Randomized Controlled Trial, Multicenter Study
- Pioglitazone and bladder cancer risk: a systematic review and meta-analysis.
Tang H, Shi W, Fu S, et al. · Cancer Med 2018 · Meta-Analysis, Systematic Review
Sponsor: Takeda
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.